Last reviewed · How we verify

Centre of Postgraduate Medical Education — Portfolio Competitive Intelligence Brief

Centre of Postgraduate Medical Education pipeline: 2 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bupivacaine Spinal 0,5% Heavy - bolus Bupivacaine Spinal 0,5% Heavy - bolus marketed Local anesthetic (amide class) Voltage-gated sodium channels Anesthesiology
Bupivacaine Spinal 0,5% Heavy - titration Bupivacaine Spinal 0,5% Heavy - titration marketed Local anesthetic (amide class) Voltage-gated sodium channels (Nav) Anesthesia
Cholecalciferol 1200 Cholecalciferol 1200 phase 3 Vitamin D supplement Vitamin D receptor (VDR) Nutritional/Metabolic

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Atlanta VA Medical Center · 1 shared drug class
  4. Barts & The London NHS Trust · 1 shared drug class
  5. Başakşehir Çam & Sakura City Hospital · 1 shared drug class
  6. Bozyaka Training and Research Hospital · 1 shared drug class
  7. Bursa City Hospital · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centre of Postgraduate Medical Education:

Cite this brief

Drug Landscape (2026). Centre of Postgraduate Medical Education — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-of-postgraduate-medical-education. Accessed 2026-05-18.

Related